Cargando…

Methods for comparative effectiveness based on time to confirmed disability progression with irregular observations in multiple sclerosis

Real-world data sources offer opportunities to compare the effectiveness of treatments in practical clinical settings. However, relevant outcomes are often recorded selectively and collected at irregular measurement times. It is therefore common to convert the available visits to a standardized sche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Debray, Thomas PA, Simoneau, Gabrielle, Copetti, Massimiliano, Platt, Robert W, Shen, Changyu, Pellegrini, Fabio, de Moor, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500950/ https://www.ncbi.nlm.nih.gov/pubmed/37303120 http://dx.doi.org/10.1177/09622802231172032

Ejemplares similares

Recommendations for the use of propensity score methods in multiple sclerosis research
por: Simoneau, Gabrielle, et al.
Publicado: (2022)

The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review
por: Karim, Mohammad Ehsanul, et al.
Publicado: (2020)

Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry
por: Simoneau, Gabrielle, et al.
Publicado: (2022)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
por: Healy, Brian C, et al.
Publicado: (2021)

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry
por: Jiang, Xiaotong, et al.
Publicado: (2023)

Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
por: Gajofatto, Alberto, et al.
Publicado: (2013)

On the aggregation of published prognostic scores for causal inference in observational studies
por: Nguyen, Tri‐Long, et al.
Publicado: (2020)

Estimating Typical Multiple Sclerosis Disability Progression Speed from Clinical Observations
por: Brown, Murray G., et al.
Publicado: (2014)

Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation
por: Jiang, Xiaotong, et al.
Publicado: (2023)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Observations on the Growth and Irregularities of Children's Teeth
Publicado: (1845)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Evidence for a two-stage disability progression in multiple sclerosis
por: Leray, Emmanuelle, et al.
Publicado: (2010)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Long-term disability progression of pediatric-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2019)

Physical activity monitoring to assess disability progression in multiple sclerosis
por: Stuart, Charlotte M, et al.
Publicado: (2020)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Radiotherapy Improves the Disability in Patients with Secondary Progressive Multiple Sclerosis
por: Ebrahimi, Hossein-Ali, et al.
Publicado: (2023)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Diagnosis and Management of Progressive Multiple Sclerosis
por: Macaron, Gabrielle, et al.
Publicado: (2019)

The Impact of Lifetime Alcohol and Cigarette Smoking Loads on Multiple Sclerosis Severity
por: Ivashynka, Andrei, et al.
Publicado: (2019)

Series of irregular observations: forecasting and model building
por: Azencott, Robert, et al.
Publicado: (1986)

Observations on the Growth and Irregularities of Children's Teeth, &c.
Publicado: (1845)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension
por: Dagan, Amir, et al.
Publicado: (2016)

Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis
por: Hänninen, Katariina, et al.
Publicado: (2020)

A multiple sclerosis disease progression measure based on cumulative disability
por: Manouchehrinia, Ali, et al.
Publicado: (2021)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)

Irregularity
por: Shepherd, S. M.
Publicado: (1859)

Irregularity
por: Forbes, Isaiah
Publicado: (1873)

Irregularities
por: Keely, G. W.
Publicado: (1887)

Irregularities
por: Robinson, J. E.
Publicado: (1887)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Neutrophils-to-Lymphocyte Ratio Is Associated with Progression and Overall Survival in Amyotrophic Lateral Sclerosis
por: Leone, Maurizio A., et al.
Publicado: (2022)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2013)

A composite measure to explore visual disability in primary progressive multiple sclerosis
por: Poretto, Valentina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_b6chvtmvrf4gogef8of2frhalr